These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 39048766)

  • 1. Unleashing the Power of Reliance for Post-Approval Changes: A Journey with 48 National Regulatory Authorities.
    Mangia F; Lin YM; Armando J; Dominguez K; Rozhnova V; Ausborn S
    Ther Innov Regul Sci; 2024 Nov; 58(6):997-1005. PubMed ID: 39048766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Worldwide Regulatory Reliance: Launching a Pilot on a Chemistry, Manufacturing, and Control Post Approval Change for a Vaccine.
    Gastineau T; Ban C; Basso A; Brehme F; Silva AL; Faure O; Palaire LL; Persaud P; Rodriguez H
    PDA J Pharm Sci Technol; 2024 Aug; 78(4):388-398. PubMed ID: 37973190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Path Forward to Optimise Post-approval Change Management and Facilitate Continuous Supply of Medicines and Vaccines of High Quality Worldwide : Joint Position from EFPIA, IFPMA and Vaccines Europe.
    Deavin A; Adam S; Ausborn S; Nielsen ASB; Cappellini S; Colmagne-Poulard I; Gastineau T; Gonzalez-Martinez A; Meillerais S; Mortazavi C
    Ther Innov Regul Sci; 2023 Jan; 57(1):7-11. PubMed ID: 35917091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Global Industry Survey on Post-Approval Change Management and Use of Reliance.
    Deavin A; Hossain A; Colmagne-Poulard I; Wong KC; Perea-Vélez M; Cappellini S; Ausborn S; Meillerais S; Bourguignon C
    Ther Innov Regul Sci; 2024 Nov; 58(6):1094-1107. PubMed ID: 39179719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Approaches to Design an Efficient, Predictable Global Post-approval Change Management System that Facilitates Continual Improvement and Drug Product Availability.
    Vinther A; Ramnarine E; Gastineau T; O'Brien L; Brehm O; Fryrear D
    Ther Innov Regul Sci; 2024 May; 58(3):433-442. PubMed ID: 38369639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Proposal of a Combined Convergence Regulatory Strategy Applied to Post-approval Changes by Latin American Countries, Reducing Workload and Allowing Continuous Improvement to Guarantee the Quality, Safety, and Efficacy of Medicines.
    Rodriguez H; De Lucia ML
    Front Med (Lausanne); 2021; 8():768376. PubMed ID: 34888329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The use of nanotechnology in medicinal products in the light of European Union law].
    Jurewicz M
    Pol Merkur Lekarski; 2014 Dec; 37(222):369-72. PubMed ID: 25715580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison between European Medicines Agency and US Food and Drug Administration in Granting Accelerated Marketing Authorizations for Covid-19 Medicines and their Utilized Regulations.
    Ghadanian M; Schafheutle E
    Ther Innov Regul Sci; 2024 Jan; 58(1):79-113. PubMed ID: 37861859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A decade of marketing approval of gene and cell-based therapies in the United States, European Union and Japan: An evaluation of regulatory decision-making.
    Coppens DGM; de Wilde S; Guchelaar HJ; De Bruin ML; Leufkens HGM; Meij P; Hoekman J
    Cytotherapy; 2018 Jun; 20(6):769-778. PubMed ID: 29730080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the new Japanese legislation for expedited approval of regenerative medicine products with the existing systems in the USA and European Union.
    Jokura Y; Yano K; Yamato M
    J Tissue Eng Regen Med; 2018 Feb; 12(2):e1056-e1062. PubMed ID: 28211195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alignment in post-approval changes (PAC) guidelines in emerging countries may increase timely access to vaccines: An illustrative assessment by manufacturers.
    Dellepiane N; Pagliusi S; Akut P; Comellas S; De Clercq N; Ghadge S; Gastineau T; McGoldrick M; Nurnaeni I; Scheppler L;
    Vaccine X; 2020 Dec; 6():100075. PubMed ID: 32995745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States.
    Salcher-Konrad M; Naci H; Davis C
    Milbank Q; 2020 Dec; 98(4):1219-1256. PubMed ID: 33021339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Granting marketing authorisation for medicines in South East European countries: the point of view of the authority.
    Tomić S; Sucić AF; Martinac AI
    Regul Toxicol Pharmacol; 2010; 57(2-3):325-32. PubMed ID: 20385190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulatory Aspects for Approval of Advanced Therapy Medicinal Products in the EU.
    Fürst-Ladani S; Bührer A; Fürst W; Schober-Ladani N
    Handb Exp Pharmacol; 2024; 284():367-387. PubMed ID: 37017789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pediatric drug development: ICH harmonized tripartite guideline E11 within the United States of America, the European Union, and Japan].
    Pflieger M; Bertram D
    Arch Pediatr; 2014 Oct; 21(10):1129-38. PubMed ID: 25175054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of regulatory pathways for the approval of advanced therapies in the European Union and the United States.
    Iglesias-Lopez C; Obach M; Vallano A; Agustí A
    Cytotherapy; 2021 Mar; 23(3):261-274. PubMed ID: 33483292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulating medicines in Europe: the European Medicines Agency, marketing authorisation, transparency and pharmacovigilance.
    Permanand G; Mossialos E; McKee M
    Clin Med (Lond); 2006; 6(1):87-90. PubMed ID: 16521363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The European Medicines Agency facilitates access to medicines in low- and middle-income countries.
    Cavaller Bellaubi M; Harvey Allchurch M; Lagalice C; Saint-Raymond A
    Expert Rev Clin Pharmacol; 2020 Mar; 13(3):321-325. PubMed ID: 32053756
    [No Abstract]   [Full Text] [Related]  

  • 19. Similarities and differences in the oncology drug approval process between FDA and European Union with emphasis on in vitro companion diagnostics.
    Senderowicz AM; Pfaff O
    Clin Cancer Res; 2014 Mar; 20(6):1445-52. PubMed ID: 24634467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. WHO collaborative registration procedure using stringent regulatory authorities' medicine evaluation: reliance in action?
    Vaz A; Roldão Santos M; Gwaza L; Mezquita González E; Pajewska Lewandowska M; Azatyan S; Saint-Raymond A
    Expert Rev Clin Pharmacol; 2022 Jan; 15(1):11-17. PubMed ID: 35130803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.